Epilepsy-Pipeline Review, H2 2015

Epilepsy-Pipeline Review, H2 2015


  • Products Id :- GMDHC7401IDB
  • |
  • Pages: 372
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Epilepsy-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Epilepsy-Pipeline Review, H2 2015', provides an overview of the Epilepsy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Epilepsy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Epilepsy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Epilepsy Overview 12

Therapeutics Development 13

Pipeline Products for Epilepsy-Overview 13

Pipeline Products for Epilepsy-Comparative Analysis 14

Epilepsy-Therapeutics under Development by Companies 15

Epilepsy-Therapeutics under Investigation by Universities/Institutes 21

Epilepsy-Pipeline Products Glance 23

Late Stage Products 23

Clinical Stage Products 24

Early Stage Products 25

Unknown Stage Products 26

Epilepsy-Products under Development by Companies 27

Epilepsy-Products under Investigation by Universities/Institutes 36

Epilepsy-Companies Involved in Therapeutics Development 38

Acorda Therapeutics, Inc. 38

Advicenne Pharma 39

Aeolus Pharmaceuticals, Inc. 40

Aequus Pharmaceuticals Inc. 41

Aestus Therapeutics, Inc. 42

Alexza Pharmaceuticals, Inc. 43

Allergan Plc 44

Anavex Life Sciences Corp. 45

Asklepios BioPharmaceutical, Inc. 46

Astellas Pharma Inc. 47

Bial-Portela & Ca, S.A. 48

BioCrea GmbH 49

Bionomics Limited 50

Biovista Inc. 51

Biscayne Pharmaceuticals, Inc. 52

Catalyst Pharmaceutical Partners, Inc. 53

Chong Kun Dang Pharmaceutical Corp. 54

Concert Pharmaceuticals, Inc. 55

Convergence Pharmaceuticals Ltd. 56

D-Pharm Ltd. 57

Eisai Co., Ltd. 58

Epirus Biopharmaceuticals, Inc. 59

Glialogix, Inc. 60

GW Pharmaceuticals Plc 61

H. Lundbeck A/S 62

Hyundai Pharmaceutical Co., Ltd. 63

INSYS Therapeutics, Inc. 64

Iproteos S.L. 65

Knopp Biosciences LLC 66

Ligand Pharmaceuticals, Inc. 67

Lipicard Technologies Limited 68

Lohocla Research Corporation 69

Mapi Pharma Ltd. 70

Marathon Pharmaceuticals, LLC 71

Marinus Pharmaceuticals, Inc. 72

MedGenesis Therapeutix Inc. 73

Neurocrine Biosciences, Inc. 74

Neuron Biopharma SA 75

Novartis AG 76

OPKO Health, Inc. 77

PharmatrophiX, Inc. 78

Promius Pharma, LLC 79

Retrophin Inc. 80

Sage Therapeutics 81

Saniona AB 82

SciFluor Life Sciences, LLC 83

SK Biopharmaceuticals Co., Ltd. 84

Sumitomo Dainippon Pharma Co., Ltd. 85

Takeda Pharmaceutical Company Limited 86

Turing Pharmaceuticals AG 87

UCB S.A. 88

Ultragenyx Pharmaceutical Inc. 89

Upsher-Smith Laboratories, Inc. 90

Vichem Chemie Research Ltd. 91

VistaGen Therapeutics , Inc. 92

Xenon Pharmaceuticals Inc. 93

XERIS Pharmaceuticals, Inc. 94

Zogenix, Inc. 95

Zynerba Pharmaceuticals, Inc. 96

Epilepsy-Therapeutics Assessment 97

Assessment by Monotherapy Products 97

Assessment by Target 98

Assessment by Mechanism of Action 103

Assessment by Route of Administration 107

Assessment by Molecule Type 109

Drug Profiles 111

2-DG-Drug Profile 111

ADV-6208-Drug Profile 113

ADV-6770-Drug Profile 114

AEOL-1114B-Drug Profile 115

AEOL-11203-Drug Profile 116

AEOL-11207-Drug Profile 117

alprazolam-Drug Profile 118

AMPX-0079-Drug Profile 120

ANAVEX-273-Drug Profile 121

AV-101-Drug Profile 122

AVL-5189-Drug Profile 124

BIS-001-Drug Profile 125

BNP-TLE-Drug Profile 126

BPS-015 SR-Drug Profile 127

brivaracetam-Drug Profile 128

BVA-601-Drug Profile 130

Cannabidiol-Drug Profile 131

carbamazepine-Drug Profile 133

CCG-63802-Drug Profile 134

Cell Therapy for Central Nervous System Disorders-Drug Profile 135

CHEC-9-Drug Profile 137

CKD-903-Drug Profile 139

clobazam-Drug Profile 140

clobazam-Drug Profile 141

CNV-1061436-Drug Profile 142

cosyntropin-Drug Profile 143

CPP-115-Drug Profile 144

CTP-354-Drug Profile 146

CUR-1916-Drug Profile 147

diazepam-Drug Profile 148

diazepam-Drug Profile 149

diazepam XeriJect-Drug Profile 151

DP-VPA-Drug Profile 152

Drug for Epilepsy-Drug Profile 154

Drug to Agonize GABA Receptor for Epilepsy-Drug Profile 155

Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders-Drug Profile 156

Epidiolex-Drug Profile 157

eslicarbazepine acetate-Drug Profile 159

everolimus-Drug Profile 163

fenfluramine hydrochloride-Drug Profile 169

fosphenytoin sodium-Drug Profile 170

FV-082-Drug Profile 171

FV-137-Drug Profile 172

ganaxolone-Drug Profile 173

Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy-Drug Profile 175

GLX-1112-Drug Profile 176

GWP-42006-Drug Profile 177

IPR-003-Drug Profile 179

IPR-131-Drug Profile 180

IPR-96-Drug Profile 181

KM-113-Drug Profile 182

KM-314-Drug Profile 183

lacosamide-Drug Profile 184

lamotrigine-Drug Profile 189

levetiracetam-Drug Profile 190

liatermin-Drug Profile 193

LSPGR-1-Drug Profile 195

LT-4121-Drug Profile 196

LT-4122-Drug Profile 197

LT-4123-Drug Profile 198

LT-4124-Drug Profile 199

LT-4125-Drug Profile 200

LT-4126-Drug Profile 201

magnesium valproate hydrate-Drug Profile 202

MB-003-Drug Profile 203

midazolam hydrochloride-Drug Profile 204

MP-101-Drug Profile 205

MP-102-Drug Profile 206

MRS-5474-Drug Profile 207

naluzotan hydrochloride-Drug Profile 208

NB-23R1-Drug Profile 209

NGT-168-Drug Profile 210

NH-34-Drug Profile 211

NRP-2945-Drug Profile 212

NST-0037-Drug Profile 214

NST-0076-Drug Profile 215

Oligonucleotide for Dravet Syndrome-Drug Profile 216

perampanel-Drug Profile 217

pregabalin ER-Drug Profile 220

propofol hemisuccinate-Drug Profile 221

SAGE-217-Drug Profile 222

SAGE-689-Drug Profile 223

SCT-66-Drug Profile 224

selurampanel-Drug Profile 225

sepranolone-Drug Profile 226

SF-0034-Drug Profile 229

simvastatin-Drug Profile 230

Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 231

Small Molecule 2 for Epilepsy-Drug Profile 232

Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 233

Small Molecule 3 for Epilepsy-Drug Profile 234

Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 235

Small Molecule 4 for Epilepsy-Drug Profile 236

Small Molecule for Epilepsy-Drug Profile 237

Small Molecule for Epilepsy-Drug Profile 238

Small Molecule for Epilepsy-Drug Profile 239

Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain-Drug Profile 240

Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy-Drug Profile 241

Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders-Drug Profile 242

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS-Drug Profile 243

Small Molecule to Inhibit ACHE for Epilepsy-Drug Profile 245

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus-Drug Profile 246

Small Molecules 1 for Epilepsy-Drug Profile 247

Small Molecules 2 for Epilepsy-Drug Profile 248

Small Molecules 3 for Epilepsy-Drug Profile 249

Small Molecules 4 for Epilepsy-Drug Profile 250

Small Molecules for CNS Disorders-Drug Profile 251

Small Molecules for Epilepsy-Drug Profile 252

Small Molecules for Epilepsy and Neuropathic Pain-Drug Profile 253

Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS-Drug Profile 254

Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus-Drug Profile 255

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders-Drug Profile 256

Small Molecules to Agonize GABA-A Receptor For Epilepsy-Drug Profile 257

Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism-Drug Profile 258

Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System-Drug Profile 259

Small Molecules to Antagonize TLR-4 for CNS Disorders-Drug Profile 260

Small Molecules to Inhibit Dynamin for Epilepsy and Oncology-Drug Profile 261

Small Molecules to Inhibit Nav1.6 for Dravet Syndrome-Drug Profile 262

Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome-Drug Profile 263

sulthiame-Drug Profile 264

TAK-935-Drug Profile 265

TF-0081-Drug Profile 266

TG-4155-Drug Profile 267

topiramate-Drug Profile 268

TPN-102-Drug Profile 269

TUR-004-Drug Profile 270

UCB-0942-Drug Profile 271

UX-007-Drug Profile 272

VAD-1-Drug Profile 274

VAD-2-Drug Profile 275

VB-3323-Drug Profile 276

VID-45110-Drug Profile 277

VU-0456810-Drug Profile 278

YKP-3089-Drug Profile 279

Z-944-Drug Profile 281

ZYN-002-Drug Profile 282

Epilepsy-Recent Pipeline Updates 283

Epilepsy-Dormant Projects 345

Epilepsy-Discontinued Products 352

Epilepsy-Product Development Milestones 354

Featured News & Press Releases 354

Appendix 362

Methodology 362

Coverage 362

Secondary Research 362

Primary Research 362

Expert Panel Validation 362

Contact Us 362

Disclaimer 363

List of Tables

Number of Products under Development for Epilepsy, H2 2015 22

Number of Products under Development for Epilepsy-Comparative Analysis, H2 2015 23

Number of Products under Development by Companies, H2 2015 25

Number of Products under Development by Companies, H2 2015 (Contd..1) 26

Number of Products under Development by Companies, H2 2015 (Contd..2) 27

Number of Products under Development by Companies, H2 2015 (Contd..3) 28

Number of Products under Development by Companies, H2 2015 (Contd..4) 29

Number of Products under Investigation by Universities/Institutes, H2 2015 31

Comparative Analysis by Late Stage Development, H2 2015 32

Comparative Analysis by Clinical Stage Development, H2 2015 33

Comparative Analysis by Early Stage Development, H2 2015 34

Comparative Analysis by Unknown Stage Development, H2 2015 35

Products under Development by Companies, H2 2015 36

Products under Development by Companies, H2 2015 (Contd..1) 37

Products under Development by Companies, H2 2015 (Contd..2) 38

Products under Development by Companies, H2 2015 (Contd..3) 39

Products under Development by Companies, H2 2015 (Contd..4) 40

Products under Development by Companies, H2 2015 (Contd..5) 41

Products under Development by Companies, H2 2015 (Contd..6) 42

Products under Development by Companies, H2 2015 (Contd..7) 43

Products under Development by Companies, H2 2015 (Contd..8) 44

Products under Investigation by Universities/Institutes, H2 2015 45

Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 46

Epilepsy-Pipeline by Acorda Therapeutics, Inc., H2 2015 47

Epilepsy-Pipeline by Advicenne Pharma, H2 2015 48

Epilepsy-Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015 49

Epilepsy-Pipeline by Aequus Pharmaceuticals Inc., H2 2015 50

Epilepsy-Pipeline by Aestus Therapeutics, Inc., H2 2015 51

Epilepsy-Pipeline by Alexza Pharmaceuticals, Inc., H2 2015 52

Epilepsy-Pipeline by Allergan Plc, H2 2015 53

Epilepsy-Pipeline by Anavex Life Sciences Corp., H2 2015 54

Epilepsy-Pipeline by Asklepios BioPharmaceutical, Inc., H2 2015 55

Epilepsy-Pipeline by Astellas Pharma Inc., H2 2015 56

Epilepsy-Pipeline by Bial-Portela & Ca, S.A., H2 2015 57

Epilepsy-Pipeline by BioCrea GmbH, H2 2015 58

Epilepsy-Pipeline by Bionomics Limited, H2 2015 59

Epilepsy-Pipeline by Biovista Inc., H2 2015 60

Epilepsy-Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015 61

Epilepsy-Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015 62

Epilepsy-Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 63

Epilepsy-Pipeline by Concert Pharmaceuticals, Inc., H2 2015 64

Epilepsy-Pipeline by Convergence Pharmaceuticals Ltd., H2 2015 65

Epilepsy-Pipeline by D-Pharm Ltd., H2 2015 66

Epilepsy-Pipeline by Eisai Co., Ltd., H2 2015 67

Epilepsy-Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 68

Epilepsy-Pipeline by Glialogix, Inc., H2 2015 69

Epilepsy-Pipeline by GW Pharmaceuticals Plc, H2 2015 70

Epilepsy-Pipeline by H. Lundbeck A/S, H2 2015 71

Epilepsy-Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015 72

Epilepsy-Pipeline by INSYS Therapeutics, Inc., H2 2015 73

Epilepsy-Pipeline by Iproteos S.L., H2 2015 74

Epilepsy-Pipeline by Knopp Biosciences LLC, H2 2015 75

Epilepsy-Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 76

Epilepsy-Pipeline by Lipicard Technologies Limited, H2 2015 77

Epilepsy-Pipeline by Lohocla Research Corporation, H2 2015 78

Epilepsy-Pipeline by Mapi Pharma Ltd., H2 2015 79

Epilepsy-Pipeline by Marathon Pharmaceuticals, LLC, H2 2015 80

Epilepsy-Pipeline by Marinus Pharmaceuticals, Inc., H2 2015 81

Epilepsy-Pipeline by MedGenesis Therapeutix Inc., H2 2015 82

Epilepsy-Pipeline by Neurocrine Biosciences, Inc., H2 2015 83

Epilepsy-Pipeline by Neuron Biopharma SA, H2 2015 84

Epilepsy-Pipeline by Novartis AG, H2 2015 85

Epilepsy-Pipeline by OPKO Health, Inc., H2 2015 86

Epilepsy-Pipeline by PharmatrophiX, Inc., H2 2015 87

Epilepsy-Pipeline by Promius Pharma, LLC, H2 2015 88

Epilepsy-Pipeline by Retrophin Inc., H2 2015 89

Epilepsy-Pipeline by Sage Therapeutics, H2 2015 90

Epilepsy-Pipeline by Saniona AB, H2 2015 91

Epilepsy-Pipeline by SciFluor Life Sciences, LLC, H2 2015 92

Epilepsy-Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 93

Epilepsy-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 94

Epilepsy-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 95

Epilepsy-Pipeline by Turing Pharmaceuticals AG , H2 2015 96

Epilepsy-Pipeline by UCB S.A., H2 2015 97

Epilepsy-Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015 98

Epilepsy-Pipeline by Upsher-Smith Laboratories, Inc., H2 2015 99

Epilepsy-Pipeline by Vichem Chemie Research Ltd., H2 2015 100

Epilepsy-Pipeline by VistaGen Therapeutics , Inc., H2 2015 101

Epilepsy-Pipeline by Xenon Pharmaceuticals Inc., H2 2015 102

Epilepsy-Pipeline by XERIS Pharmaceuticals, Inc., H2 2015 103

Epilepsy-Pipeline by Zogenix, Inc., H2 2015 104

Epilepsy-Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 105

Assessment by Monotherapy Products, H2 2015 106

Number of Products by Stage and Target, H2 2015 108

Number of Products by Stage and Mechanism of Action, H2 2015 113

Number of Products by Stage and Route of Administration, H2 2015 117

Number of Products by Stage and Molecule Type, H2 2015 119

Epilepsy Therapeutics-Recent Pipeline Updates, H2 2015 292

Epilepsy-Dormant Projects, H2 2015 354

Epilepsy-Dormant Projects (Contd..1), H2 2015 355

Epilepsy-Dormant Projects (Contd..2), H2 2015 356

Epilepsy-Dormant Projects (Contd..3), H2 2015 357

Epilepsy-Dormant Projects (Contd..4), H2 2015 358

Epilepsy-Dormant Projects (Contd..5), H2 2015 359

Epilepsy-Dormant Projects (Contd..6), H2 2015 360

Epilepsy-Discontinued Products, H2 2015 361

Epilepsy-Discontinued Products (Contd..1), H2 2015 362

List of Figures

Number of Products under Development for Epilepsy, H2 2015 22

Number of Products under Development for Epilepsy-Comparative Analysis, H2 2015 23

Number of Products under Development by Companies, H2 2015 24

Number of Products under Investigation by Universities/Institutes, H2 2015 30

Comparative Analysis by Late Stage Development, H2 2015 32

Comparative Analysis by Clinical Stage Development, H2 2015 33

Comparative Analysis by Early Stage Products, H2 2015 34

Assessment by Monotherapy Products, H2 2015 106

Number of Products by Top 10 Targets, H2 2015 107

Number of Products by Stage and Top 10 Targets, H2 2015 107

Number of Products by Top 10 Mechanism of Actions, H2 2015 112

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 112

Number of Products by Top 10 Routes of Administration, H2 2015 116

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 116

Number of Products by Molecule Types, H2 2015 118

Number of Products by Stage and Molecule Types, H2 2015 118

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acorda Therapeutics, Inc.

Advicenne Pharma

Aeolus Pharmaceuticals, Inc.

Aequus Pharmaceuticals Inc.

Aestus Therapeutics, Inc.

Alexza Pharmaceuticals, Inc.

Allergan Plc

Anavex Life Sciences Corp.

Asklepios BioPharmaceutical, Inc.

Astellas Pharma Inc.

Bial-Portela & Ca, S.A.

BioCrea GmbH

Bionomics Limited

Biovista Inc.

Biscayne Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc.

Chong Kun Dang Pharmaceutical Corp.

Concert Pharmaceuticals, Inc.

Convergence Pharmaceuticals Ltd.

D-Pharm Ltd.

Eisai Co., Ltd.

Epirus Biopharmaceuticals, Inc.

Glialogix, Inc.

GW Pharmaceuticals Plc

H. Lundbeck A/S

Hyundai Pharmaceutical Co., Ltd.

INSYS Therapeutics, Inc.

Iproteos S.L.

Knopp Biosciences LLC

Ligand Pharmaceuticals, Inc.

Lipicard Technologies Limited

Lohocla Research Corporation

Mapi Pharma Ltd.

Marathon Pharmaceuticals, LLC

Marinus Pharmaceuticals, Inc.

MedGenesis Therapeutix Inc.

Neurocrine Biosciences, Inc.

Neuron Biopharma SA

Novartis AG

OPKO Health, Inc.

PharmatrophiX, Inc.

Promius Pharma, LLC

Retrophin Inc.

Sage Therapeutics

Saniona AB

SciFluor Life Sciences, LLC

SK Biopharmaceuticals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Takeda Pharmaceutical Company Limited

Turing Pharmaceuticals AG

UCB S.A.

Ultragenyx Pharmaceutical Inc.

Upsher-Smith Laboratories, Inc.

Vichem Chemie Research Ltd.

VistaGen Therapeutics , Inc.

Xenon Pharmaceuticals Inc.

XERIS Pharmaceuticals, Inc.

Zogenix, Inc.

Zynerba Pharmaceuticals, Inc.

Epilepsy Therapeutic Products under Development, Key Players in Epilepsy Therapeutics, Epilepsy Pipeline Overview, Epilepsy Pipeline, Epilepsy Pipeline Assessment

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com